🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Utah Medical Products, Inc. UTMD R2KR3KPHARMA

Healthcare · Medical Instruments & Supplies · United States
https://www.utahmed.com
Company Profile ↓
$71.25
+22.34% 1Y
Mkt Cap$226.86M
P/E21.72
P/B1.87
Div. Yield1.77%
52W High$73.97
52W Low$53.01
Book Value$37.80
EPS (TTM)$3.28

Company Overview

Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; BioPharm HP-PRT; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health center in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

Why Investors Should Care

Reasonable Valuation

Trades at a P/E of 21.7, below the sector median of 25.2.

Healthy Margins

Maintains a net profit margin of 29.0%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.16.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $38.52M (-5.8% YoY).
  • Trailing 12 Months Year-on-year growth — revenue -14.3%, earnings -10.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 2.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:2.51%
1 Year:-14.30%

Compounded Profit Growth

5 Years:-
1 Year:-10.10%

Stock Price Performance

1 Year:+22.34%
6 Months:+10.45%
3 Months:+5.81%
1 Month:+1.83%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 87% of range
$53.01 $73.97
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)50.76 · Neutral
Price Performance
1M+1.83%
3M+5.81%
6M+10.45%
1Y+22.34%
Valuation vs Sector

P/E of 21.72 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Excellent profit margin of 29.0%.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
21.72
Industry PE
25.17
Forward P/E est.
24.16
PEG Ratio
4.25
Book Value
$37.80
Price to Book
1.87
P/S
6.25
EV/EBITDA
9.26
Dividend Yield
1.77%

Growth (CAGR)

Revenue 5Y
2.51%
Profit 5Y
-
Revenue (YoY)
-14.30%
Earnings (YoY)
-10.10%

Profitability & Returns

ROCE
9.51%
ROE
8.76%
ROA
6.10%
Profit Margin
29.04%
Op Margin
36.89%
Gross Margin
57.90%
EPS (Latest Qtr)
$0.82
EPS (TTM)
$3.28

Balance Sheet & Liquidity

Debt/Equity
0.16
Quick Ratio
44.01
Current Ratio
48.62
Debt
$194.00K
Total Assets
$124.38M
Current Assets
$97.74M
Working Capital
$95.14M

Ownership

Promoter Holding
7.18%
Chg in Prom Hold
-0.00%
FII / Inst Holding
76.80%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$226.86M
Total Revenue (TTM)
$36.11M
EBITDA
$14.82M
Free Cash Flow
$14.32M
Operating Cash Flow
$14.69M
Shares Outstanding
3.18M
Gross Margin
57.90%
Payout Ratio
37.64%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 UTMD Utah Medical Products, Inc. R2KR3KPHARMA 71.25 21.72 $226.86M 1.77% 9.51% 8.76% 2.51% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ---10.26M10.83M10.12M10.20M10.89M10.96M10.39M9.76M10.73M11.85M12.49M11.83M10.90M8.79M10.48M12.01M10.96M12.60M12.57M12.91M12.32M13.43M12.96M13.57M12.52M12.87M12.51M12.33M11.34M10.40M10.01M9.16M9.71M9.95M9.81M9.04M8.72M
Gross Profit 6.22M6.25M5.78M6.54M6.89M6.50M6.47M6.92M6.98M6.29M6.11M6.77M7.50M7.38M7.81M6.84M4.95M6.50M7.26M6.95M7.79M8.07M8.11M7.53M8.15M8.19M8.33M7.84M7.74M7.36M7.10M6.77M6.25M5.80M5.32M5.54M5.59M5.60M5.26M5.28M
Operating Income 4.31M4.32M3.94M4.72M5.03M4.68M-4.97M5.06M4.40M-4.10M4.48M4.37M-3.86M1.98M3.59M-3.89M4.76M5.10M-4.52M5.06M5.14M-4.44M4.42M3.97M-3.88M3.44M3.34M-3.15M3.20M2.61M-2.56M
Diluted EPS 0.850.860.780.951.040.97-0.671.091.151.800.910.840.940.991.170.840.360.800.940.830.941.151.130.961.121.181.251.161.151.081.181.090.981.030.860.920.940.820.800.82
R&D Expense 110.00K119.00K135.00K118.00K119.00K103.00K-113.00K117.00K108.00K-115.00K113.00K130.00K-135.00K116.00K125.00K-130.00K128.00K127.00K-123.00K135.00K112.00K-144.00K133.00K138.00K-266.00K255.00K172.00K-154.00K135.00K167.00K-154.00K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 25.92M25.12M37.86M41.55M40.49M41.28M40.16M39.30M41.41M42.00M46.90M42.18M49.05M52.28M50.22M40.90M38.52M
Gross Profit 13.79M13.21M22.40M25.31M24.27M24.98M24.18M23.69M26.39M26.31M29.47M25.55M30.92M32.20M30.04M24.14M22.00M
Operating Income 9.43M8.92M11.84M15.20M14.83M16.20M15.65M16.19M19.01M18.70M17.63M13.71M18.88M19.79M16.78M13.59M11.40M
Diluted EPS 1.721.652.032.743.023.023.143.222.284.953.942.944.044.524.573.963.48
R&D Expense 361.00K397.00K-518.00K563.00K491.00K460.00K522.00K475.00K447.00K454.00K483.00K486.00K526.00K493.00K560.00K813.00K668.00K

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --41.24M76.39M76.94M80.71M81.08M79.17M76.19M92.75M99.77M109.79M111.75M-123.87M135.46M122.54M122.54M
Current Assets --------------89.92M106.27M96.33M97.74M
Cash & Equivalents 97.00K410.00K3.82M6.53M8.87M14.39M19.27M23.28M26.30M39.88M51.11M42.79M51.59M-75.05M92.87M82.98M85.76M
Inventory --------------8.81M9.58M8.81M7.93M
Receivables --------------5.54M3.49M4.24M4.04M
Total Liabilities --3.45M35.63M25.96M20.13M16.52M9.53M6.95M14.62M10.78M8.69M8.92M-9.62M7.14M5.11M3.27M
Current Liabilities --1.90M9.63M7.82M7.61M8.97M4.07M3.02M5.28M5.26M3.45M3.79M-5.96M4.71M3.76M2.60M
Long Term Debt -----9.00K5.07K1.01K-0000-----
Total Debt --------------341.00K295.00K282.00K225.00K
Total Equity --37.79M40.76M50.97M60.58M64.56M69.65M69.24M78.12M88.99M101.09M102.82M-114.25M128.31M117.43M119.27M
Shares Outstanding --------------3.63M3.63M3.34M3.19M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 7.23M7.16M11.37M13.56M12.31M15.39M13.80M14.53M16.91M16.83M17.06M20.14M21.20M21.15M22.28M14.83M14.69M
Investing Cash Flow -3.16M2.71M-26.68M-208.00K-344.00K-1.13M-246.00K-3.30M-1.60M534.00K-21.54M-860.00K-552.00K-818.00K-639.00K-208.00K-371.00K
Financing Cash Flow -3.77M-6.42M18.08M-11.17M-6.60M-8.26M-8.89M-6.34M-2.65M-4.78M-4.23M-10.73M-10.90M-5.48M-4.17M-23.84M-12.34M
Capital Expenditure -466.00K-1.53M-247.00K-254.00K-339.00K-1.11M-176.00K-3.29M-1.60M-402.00K-540.00K-860.00K-552.00K-809.00K-639.00K-230.00K-371.00K
Free Cash Flow 6.76M5.62M11.12M13.31M11.97M14.28M13.62M11.23M15.31M16.43M16.52M19.28M20.65M20.34M21.64M14.60M14.32M
Share Buybacks --------01.21M398.00K6.98M02.50M019.97M8.36M
Dividends Paid 3.34M6.03M3.43M3.56M3.67M3.77M3.85M3.92M2.96M4.03M4.11M4.12M11.46M3.16M4.28M4.26M3.98M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 53.2%52.6%59.2%60.9%59.9%60.5%60.2%60.3%63.7%62.6%62.8%60.6%63.0%61.6%59.8%59.0%57.1%
Operating Margin % 36.4%35.5%31.3%36.6%36.6%39.3%39.0%41.2%45.9%44.5%37.6%32.5%38.5%37.9%33.4%33.2%29.6%
Net Margin % -----------------
ROE % -----------------
ROCE % -22.7%17.7%22.0%20.3%22.5%20.8%22.1%21.7%19.8%16.6%12.7%-16.8%12.8%11.4%9.5%

Shareholding Pattern

Insiders
7.18%
Institutions
76.80%
Public Float
82.74%

Top Institutional Holders

#Holder% HeldSharesValue
1 Brandes Investment Partners L.P. 14.92% 475.16K $34.58M
2 Blackrock Inc. 6.40% 203.69K $14.82M
3 Dimensional Fund Advisors LP 6.24% 198.82K $14.47M
4 Renaissance Technologies, LLC 5.52% 175.81K $12.79M
5 Vanguard Capital Management LLC 4.23% 134.53K $9.79M
6 Geode Capital Management, LLC 3.39% 108.05K $7.86M
7 Minerva Advisors LLC 2.94% 93.61K $6.81M
8 Hotchkis & Wiley Capital Management, LLC 2.68% 85.23K $6.20M
9 Rice, Hall, James & Associates LLC 2.24% 71.36K $5.19M
10 Morgan Stanley 2.19% 69.67K $5.07M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for UTMD

Google News hu, 03 Sep 2026

Why (UTMD) Price Action Is Critical for Tactical Trading - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNbzA3UkpLWlhrMkxkOUh0Y3hjNFR3a05yeXlHMklKMTNnR1c4TFRKUFJZaUNVS0pUQXEwNEZCWkpBN1pLQzhONkIxcTRzNFdoV1k0YWZ0SmhPb2cxdExYQjFveHBlS2xCTjNFN0c0SXpSVDFqLVJncnc5bGFNd0o1bng0YXVJeUx4TUhGLW…

Google News ue, 01 Sep 2026

Breaking News about Utah Medical Products, Inc. - Common Stock (Nasdaq:UTMD) - FinancialContent

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9KZHRzd09PS1lzLVFNVURSdC1sWHV5UTFqNHhyWl9xQTM3NlU5NEp1aW42Uk1SRlNUX2hnd1hjdFJobDZUMWI5MDZNRlFqanhpbGtnUnBFN0VOMmoxVnZzVg?oc=5" target="_blank">Breaking News about Utah Medical Prod…

Google News Sat, 25 Jul 2026

Utah Medical Products (UTMD) Stock Margins Slip To 29% Net Profit Challenging Bullish Narratives - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxOTWdRQkZFY0lFNFljVFZWZWpaZGhDVEVGU1ZIZGVhN2NEN3V2UWJZZDdRUHZ1dEhRWlJJeXBoXzZLUDhRV3RZeE8tQWhUWDJTNXpsY3ctTjVGOHZweUhDdk1SaDJHaldaNzJOd3prd19YNkxpWGR2Si1mWjV1djQxRkpvUGhXbkpDU3cwU2…

Google News Wed, 26 Aug 2026

Utah Medical Products: Healthy Cash Holdings, But Declining Revenue Is A Cause For Concern - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNMERuSzBjbEU1UGtLbFhTeFVUcm12SUVLRlhYX1lDZ0RTZnBteENuNVhzTzZHOE1kTjVsNC1lUjc0VWVzdk5NUUVQTmlNNnV2SEt2UFc5M3NmZ3FrY24xNjdHOVNvZTFGaTB1bVo3TXVPLUZjRUVqdm5tT2tZZF9vSERWT0lyaEZfZi1yM0…

Google News Fri, 14 Aug 2026

Brandes Investment Partners reports 14.9% Utah Medical Products (UTMD) stake - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNZlplcWJZaUZCY1FEcnlzS2k5SzRZRXFTV1FuMkstRTJJZE1GSHBQNnRWVFRrb1hjMFN5cFhqMzRLZl9jUF82c1U5OUExOGNZbHZmcE9KbmRIVHMtY01ibmFTekpRYUctX1pHcjdwUldoSDdDOTJnWWk5ZjhTcDB5amhJY3pZTS1KbmpiWE…

Google News Sat, 30 May 2026

UTMD - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9jUFl3RkFLeXlCcER6b3dLTTVlM0pVYy1MYlBkWmJIMkpKNU1nNGY2ak82ZDh0NlViTmlOckdXTEhKV1VBdEE?oc=5" target="_blank">UTMD</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

UTMD — Frequently Asked Questions

What is the current share price of Utah Medical Products, Inc. (UTMD)?

As of 2026-09-07 16:24 PDT, Utah Medical Products, Inc. (UTMD) trades at $71.25 on NasdaqGS. Its 52-week range is $53.01 to $73.97.

What is the market capitalisation of UTMD?

Utah Medical Products, Inc. (UTMD) has a market capitalisation of $226.86M on NasdaqGS.

What is the P/E ratio of UTMD?

UTMD trades at a trailing price-to-earnings (P/E) ratio of 21.72. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.87.

Does UTMD pay a dividend?

Utah Medical Products, Inc. (UTMD) currently offers a dividend yield of 1.77%.

What is the return on equity (ROE) of UTMD?

UTMD has a return on equity (ROE) of 8.76%. Its return on capital employed (ROCE) is 9.51%.

Is UTMD a good stock to buy?

This page provides a data-driven analysis of Utah Medical Products, Inc. (UTMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space